A β-Cyclodextrin-Based Nanoparticle with Very High Transfection Efficiency Unveils siRNA-Activated TLR3 Responses in
Cristina de la Torre1,2, Pablo Játiva1,2, Inmaculada Posadas1,2
1Unidad Asociada Neurodeath, Facultad de Medicina, Universidad de Castilla-La Mancha, 02006 Albacete, Spain.
Pharmaceutics
|November 11, 2022
Summary
This study developed a novel nanoparticle for delivering small interfering RNAs (siRNAs) to cancer cells. While aiming to enhance chemotherapy, the siRNAs unexpectedly triggered an immune response, offering a potential new strategy for prostate cancer treatment.
Area of Science:
- Biotechnology and Nanomedicine
- Molecular Biology and Genetics
- Cancer Research and Therapeutics
Background:
- Small interfering RNAs (siRNAs) offer specific gene silencing but require protection and delivery systems due to their instability.
- Nanoparticle-based delivery is crucial for efficient cellular uptake and therapeutic application of siRNAs.
Purpose of the Study:
- To evaluate a Janus-type polycationic amphiphilic β-cyclodextrin derivative for siRNA delivery.
- To assess the combined effect of simultaneous knockdown of p42-MAPK and Rheb with docetaxel (DTX) in prostate cancer cells.
- To investigate potential off-target effects and unintended immune responses induced by siRNA delivery.
Main Methods:
- Transfection of siRNAs targeting p42-MAPK and Rheb into cancer cell lines and astrocytes using a novel β-cyclodextrin derivative.
- Evaluation of docetaxel (DTX) toxicity following simultaneous gene knockdown in LNCaP and PC3 prostate cancer cells.
- Analysis of siRNA-induced off-target effects, including toll-like receptor 3 (TLR3) activation and downstream immune signaling.
Main Results:
- The developed nanoparticle efficiently delivered siRNAs into various cell types.
- Simultaneous knockdown of p42-MAPK and Rheb enhanced DTX toxicity in LNCaP cells but not PC3 cells.
- Off-target effects were observed, characterized by TLR3 activation, leading to β-interferon and caspase activation.
Conclusions:
- The novel β-cyclodextrin nanoparticle is an effective system for siRNA delivery.
- The observed siRNA-induced immune activation via TLR3 presents a potential strategy for eliciting an anti-cancer immune response.
- This immune-stimulating mechanism could be repurposed for therapeutic applications in prostate cancer treatment.
